ABSTRACT Background: Epidemiologic studies suggest that diets with a low glycemic index (GI) or glycemic load (GL) are associated with a decreased risk of developing metabolic syndrome. Intervention studies are inconsistent, however, possibly due to differences in macronutrient and fiber compositions of the experimental diets. Objective: We tested side-by-side test foods with similar macronutrient and fiber compositions but with different sucrose-flour ratios or carbohydrate source to determine the effects of different GIs and GLs on metabolic risk markers in overweight subjects. Design: Overweight men (n = 9) and women (n = 6) received in random order for 11 wk 4 test foods with an increased GI or a decreased GI (69 compared with 40, 86 compared with 48, 63 compared with 37, and 51 compared with 20, respectively). There was a GL difference of 32 units between the 2 interventions. Results: At the end of the 11-wk intervention periods, the decreased GL test foods did not change fasting plasma glucose (mean 6 SD: 5.83 6 0.6 compared with 5.94 6 0.6 mmol/L) or insulin (8.3 6 2.8 compared with 9.8 6 5.1 mU/L) concentrations compared with increased GL test foods. Serum total cholesterol (5.56 6 0.90 compared with 5.76 6 1.04 mmol/L), LDL-cholesterol (3.57 6 0.72 compared with 3.68 6 0.80 mmol/L), HDL-cholesterol (1.21 6 0.38 compared with 1.24 6 0.37 mmol/L), and triacylglycerol (1.61 6 0.77 compared with 1.78 6 1.04 mmol/L) concentrations were also not significantly different for decreased and increased GL test foods, respectively. Finally, proinflammatory (high-sensitivity C-reactive protein, interleukin-6, tumor necrosis factor-a, monocyte chemoattractant protein 1) and prothrombotic (plasminogen activator inhibitor 1) markers were not affected. Glucose and lipids were also analyzed after 1 and 5 wk of intervention and were not affected by the intervention. Conclusion: When incorporated into a habitual diet, consumption of test foods with a decreased GL does not ameliorate metabolic risk markers in overweight subjects.
INTRODUCTION
It is becoming increasingly established that metabolic syndrome and its associated risk factors are related to an increased incidence of type 2 diabetes (T2D) and cardiovascular disease (CVD) (1) . Because diet is a first-line intervention in the prevention and treatment of these risk factors, many studies have been initiated to examine the effects of diets and dietary components on these metabolic risk factors. In this respect, growing attention is paid to different kinds of carbohydrates. There are many different carbohydrates and many different classifications have been used to describe them. For one of these classifications, Jenkins et al (2) have introduced the concept of the glycemic index (GI). This scale ranks carbohydrate-rich foods by how much they raise blood glucose concentrations compared with a standard food (either white bread or a glucose solution). The idea behind this concept is that increased postprandial glucose concentrations have a negative effect on several metabolic risk factors. The GI of a food is not only determined by the nature of the carbohydrate but also by other dietary factors that affect nutrient digestibility or insulin secretion. Epidemiologic studies have now shown that high-GI diets are associated with an increased risk to develop T2D and CVD (3) (4) (5) . However, the GI does not relate to the amount of carbohydrates in the diet; it only reflects the quality of the carbohydrate. Yet, the quantity of carbohydrate is also an important determinant of postprandial glucose increases. Therefore, the concept of the dietary glycemic load (GL) was developed (6) . The GL is the product of a food's GI and its total available carbohydrate content. Several observational studies have suggested that diets high in GL are related to an increased risk to develop diet-related diseases, such as T2D (7) (8) (9) and CVD (10, 11) . However, the GL has been criticized because results of intervention studies are less convincing. This may in part be due to the fact that most studies so far have been performed with food products that not only differed in GL but also in fiber, fat, or protein contents. It is well known that these dietary components also affect glucose and lipid metabolism. Thus, it is not always possible to disentangle the metabolic effects of the GI from those of other dietary components.
Therefore, the objective of the present study was to examine the short-term (1 and 5 wk) and longer-term (11 wk) effects of the consumption of different GL test foods on changes in metabolic risk factors in subjects at increased risk of developing metabolic syndrome. Toward this end, 4 test foods were developed that yielded increased and decreased glycemic responses. In these test foods, the form of available carbohydrate was exchanged to create differences in GI and GL, although amounts of the other macronutrients and of dietary fiber were comparable between the 2 variants.
SUBJECTS AND METHODS

Study population
Recruitment of subjects started in April 2006 via posters at Maastricht University and hospital buildings, by advertisements in local newspapers, and by soliciting subjects who had participated in earlier studies at our department and who had indicated that they were interested to participate in other studies. Sixty-six subjects expressed their interest and received an information brochure about the purposes and requirements of the study. Thirtynine subjects who met our first selection criteria were willing to participate and were invited for 2 screening visits. These subjects were aged between 30 and 65 y and had 2 characteristics related to metabolic syndrome according to the Adult Treatment Panel: National Cholesterol Education Program III guidelines (12) . The screening visit consisted of 2 fasted blood samples taken with an interval of 3 d for analyses of plasma glucose, serum lipids, lipoproteins, and hematologic variables. In addition, waist circumference, weight, height, and blood pressure were measured. Finally, all subjects completed a general and medical questionnaire. Only subjects that met 2 of the following 5 criteria were invited to participate: fasting plasma glucose .5.6 mmol/L, elevated triglycerides (.1.7 mmol/L), decreased HDL cholesterol (,1.03 mmol/L for men and ,1.3 mmol/L for women), increased waist circumference (.102 cm for men and .88 cm for women), or elevated blood pressure (130/85 mm Hg). Individuals who reported taking medications for blood pressure were excluded. In addition, subjects did not intend to change their physical activity pattern during the study, did not use medication or a prescribed diet known to affect lipid and glucose metabolism, did not use illicit drugs or abuse alcohol, were not pregnant or breastfeeding, did not have a history of coronary heart disease, cancer, diabetes, familial hypercholesterolemia, an abnormal hematologic profile, and kidney, liver, or pancreatic disease or malignancies ,5 y ago. Blood donation or participation in another biomedical trial was not allowed 30 d before or during the study. Finally, 20 subjects started the study, 6 women and 14 men. Subjects withdrew after the first experimental period of the study mainly for reasons specifically related to the strict study protocol (n = 3) or stressful personal and job circumstances (n = 1). During the second experimental period, one male subject returned .50% of the provided test foods to the university. Because of poor compliance, his results were excluded from further analyses. Thus, results for 15 subjects, 9 men and 6 women, were used ( Table 1) . The Medical Ethical Committee of the University of Maastricht (Netherlands) approved the study, and all subjects provided signed informed consent before entering the study.
Study design
The study was designed as a randomized, double-blinded, controlled crossover design with 2 successive periods of 14 wk each. Four different test foods were used: bread, fruit drink, a cake, and a cookie. All products were made from commercially available ingredients and prepared according to common procedures. For each test food, there were 2 variants. The variant with the higher GI is referred to as the increased GI (iGI) test food, and the variant with the lower GI is referred to as the decreased GI (dGI) test food. The iGIs and dGIs of the test foods were as follows: for bread, 69 compared with 40; for the fruit drink, 86 compared with 48; for cake, 51 compared with 20; and for the cookie, 63 compared with 37, respectively. These GIs were determined in a previous study (13) according to a standardized protocol. The 2 kinds of bread, cake, and cookie differed only in sucrose-flour ratio, whereas the energy, total fiber, fat, and protein contents were comparable ( Table 2) . Fruit drinks were composed of 2 different sources of carbohydrates [isomaltulose (GI of 32) or sucrose (GI of 61)]. Isomaltulose is a natural disaccharide that is structurally related to sucrose but is more slowly hydrolyzed and absorbed. Thus, the differences in GI were created by changing the source of carbohydrates. During the previous study (13) , subjects also had to complete questionnaires. None of the volunteers reported any complaints about the taste, smell, or texture of the test foods or thought consuming the products for a longer time period was difficult.
Before the study started, the subjects were randomly allocated to 1 of 2 possible dietary intervention groups. During a run-in period of 3 wk, each subject consumed a diet providing the 4 different dGI test foods. The first group continued to consume the dGI test foods, whereas the second group consumed the iGI test foods for 11 wk. Thereafter, the volunteers followed a washout period for 2 wk, during which time they consumed their habitual diets. After that, each subject again consumed the dGI test foods for a period of 3 wk. Subjects then crossed over to the other diet. To avoid weight gain, subjects had to consume these test foods instead of their normal food items. Before the study, replacement and consumption of daily food products by our test foods was discussed with the dietitian. Instead of their regular bread, participants had to consume our test breads in the morning and at lunch. They also had to replace their regular snacks with our test cookies and test cake. Finally, subjects were instructed not to consume soft drinks and to replace these by 2 bottles of our test fruit drink, one at lunch and one at dinner. Thus, dietary advice was given to replace similar products and to maintain constant body weight. However, 2 diets were consumed that differed in GI but not in amounts of energy, carbohydrates, protein, fat, and dietary fiber. Body weight without shoes or heavy clothes was recorded at day 0 and at the end of each run-in (day 21) and experimental period. In a diary, participants had to record any signs of illness, medication used, alcohol consumption, menstrual phase, any deviations to the study protocol, and any side effects experienced (eg, headache, stomach complaints, nausea, diarrhea, flatulence, constipation). Other possible side effects were monitored by assessing hematologic variables and indexes to measure kidney and liver function at day 0 and at the end of each run-in and intervention period. At the end of each run-in and experimental period, subjects recorded their food intake for the previous 3 wk by completing food-frequency questionnaires (FFQs) to estimate their energy and nutrient intakes (14) . We also calculated the GL of the test foods by multiplying the GI with the actual amount of carbohydrates provided by that test food (6) . FFQs were checked by a registered dietitian in the presence of the subjects.
Blood sampling
At the start of both periods and after 3, 4, 8, 13, and 14 wk of intervention, blood samples were collected after an overnight fast. Therefore, participants were instructed not to use alcohol during the previous day and not to smoke on the morning before blood sampling. Tea, without sucrose or milk, and water were allowed. Venous blood was collected between 0730 and 1100 from the anticubital vein by using a Vacutainer system (Becton Dickinson, Franklin Lakes, NJ) with the volunteer in a recumbent position. Venipuncture was performed under standardized conditions by using a 0.9 · 38-mm needle by the same person, in the same room, at the same time of the day, and on the same weekday for each subject.
Plasma measurements
Blood was sampled in a 10-mL EDTA-coated tube at weeks 3, 4, 13, and 14 for analysis of insulin, high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), and tumor necrosis factora (TNF-a). At all time points, 4 mL of blood was collected in a sodium fluoride tube for analysis of glucose. Finally, 2.7 mL of blood was collected in an anticoagulant tube (sodium citrate) for analysis of the prothrombotic marker plasminogen activator inhibitor 1 (PAI-1) at weeks 3, 4, 13, and 14. These tubes were kept on ice and centrifuged 1 h after venipuncture (2000 g for 30 min at 4°C), and samples were snap-frozen in liquid nitrogen and stored at 280°C for later analyses.
Serum measurements
Ten milliliters of blood were collected in a serum separator tube for analyses of serum lipids at all time points (total serum cholesterol, HDL cholesterol, total triacylglycerols); apolipoprotein (apo) A-I and apo B were measured at weeks 3 and 4 and in a pooled sample of weeks 13 and 14; serum fructosamine was measured at weeks 3, 4, 13, and 14; and indexes of kidney and liver function were determined at weeks 3, 4, and 14. After blood was allowed to clot for 30 min at room temperature, serum was obtained by centrifuging at 2000 · g for 30 min at room temperature. Serum samples were then stored in small portions at 280°C until later analyses.
Glucose metabolism
Plasma concentrations of glucose were analyzed enzymatically by using the hexokinase method (Roche Diagnostic Systems, Hoffmann-La Roche Ltd, Basel, Switzerland). Insulin was measured by using an enzymatic assay (Mercodia, Uppsala, Sweden). The homeostasis model assessment of relative insulin resistance (HOMA-IR), a measure of insulin sensitivity, was calculated as described by Matthews et al (15) . Serum fructosamine was measured enzymatically by using the hexokinase method (Roche Diagnostic Systems). Glycated hemoglobin concentrations were measured at the same intervals with the VARIANT Hemoglobin Testing Systems HbA 1 /HBA 2 Dual Kit (Bio-Rad Laboratories, Milan, Italy).
Lipid metabolism
In all samples, serum total cholesterol (CHOD-PAP method; Roche Diagnostic Systems), HDL cholesterol (precipitation method; Roche Diagnostic Systems), and triacylglycerol (16) with correction for free glycerol (GPO Trinder; Sigma Diagnostics, St Louis, MO) were analyzed. Serum LDL-cholesterol concentrations were calculated by using the equation of Friedewald et al (17) . Apo A-I and apo B concentrations were analyzed by using an immunoturbidimetric method (UNI-KIT apo A-I and UNI-KIT apo B; Roche Diagnostic Systems).
Inflammation and prothrombotic markers
Plasma hs-CRP concentrations were measured with a highly sensitive immunoturbidimetric assay (Kamiya Biomedical Co, Seattle, WA). Plasma concentrations of TNF-a and IL-6 were determined by an enzymatic assay (R&D Systems, Abingdon, United Kingdom). Enzymatic assays were used for the measurement of plasma concentrations of monocyte chemoattractant protein 1 (MCP-1; MSD 96-well MULTI-SPOT Custom Cytokine Assay; Meso Scale Discovery, Gaithersburg, MD). PAI-1 activity was measured in citrated plasma by using an enzymatic assay (Chromolize PAI-1; Biopool, Umea, Sweden).
Side effects
Hematologic variables (ie, number of white blood cells, percentage of lymphocytes, percentage of monocytes, percentage of granulocytes, number of red blood cells, hemoglobin, hematocrit, mean corpuscular volume, and number of platelets) were measured at weeks 3, 4, 13, and 14 on a Coulter AcT diff (Coulter Corporation, Miami, FL) by routine procedures. Serum samples were analyzed to determine parameters of liver function [alanine transaminase (ALT), aspartate aminotransferase (AST), c-glutamyl transpeptidase, alkaline phosphatise, and total bilirubin] and kidney function (creatinine). These measurements were performed by using a Beckman Coulter Synchron LX20 PRO Clinical System (Beckman Coulter Inc, Fullerton, CA).
Statistical analyses
Changes in serum HDL-cholesterol concentrations were the main outcome measure. Before the start of the study, it was calculated that 14 participants were needed to reach a power of 80% to detect a true difference in HDL cholesterol of 0.08 mmol/L with a = 0.05. Differences between female and male subjects in baseline characteristics were analyzed with an unpaired Student's t test. For each subject, glucose, insulin, serum lipid, and lipoprotein values from weeks 13 and 14 were averaged before statistical analyses. Differences between the dietary periods in values from weeks 0 (baseline), 3, 4, and 8 and between the end of the study (average of weeks 13 and 14) of the increased GL (iGL) and decreased GL (dGL) periods were evaluated by paired Student's t test. Results are expressed as means 6 SDs (18). A P value , 0.05 was considered statistically significant. Statistical analyses were performed by using SPSS version 15.0 for Windows (SPSS Inc, Chicago, IL).
RESULTS
Side effects
Side effects were monitored by assessing hematologic variables and indexes of kidney and liver function. Throughout the study, all variables remained within the normal range for all subjects, and no treatment effects were present. Compared with other subjects, however, AST and ALT values consistently increased for one subject during the period in which he consumed dGL test foods (AST and ALT values at week 3 were 62 and 70 U/L, and those at week 14 were 56 and 68 U/L, respectively). When results for this subject were excluded from the statistical analyses, the conclusions did not change.
Dietary intake
As calculated from the returned products, daily consumption of the bread, cake, cookie, and fruit drink was similar after the iGL and dGL intervention periods. The test foods contributed to 26 6 8% of energy of total energy intake in both diet periods. There were also no differences in the contributions of the iGL and dGL test foods to intakes of carbohydrate (19% of energy), total fat (4% of energy), and protein (2% of energy). Results of the FFQs were unchanged at the end of the 2 dietary periods (iGL and dGL) with regard to intakes of total daily energy (8.4 6 1.7 compared with 8.0 6 1.5 MJ), macronutrients (carbohydrate: 51.2 6 6.6% compared with 51.6 6 5.3% of energy; protein: 16.0 6 2.4% compared with 15.4 6 2.1% of energy; and fat: 30.1 6 4.7% compared with 30.4 6 4.9% of energy), fiber (2.5 6 0.5 compared with 2.5 6 0.5 g/MJ), and alcohol (3.0 6 3.4% compared with 3.4 6 3.2% of energy) ( Table 3) . As expected, the GL (68 6 22 compared with 36 6 11) as provided by the test foods was significantly reduced (P , 0.001) during the period in which dGI test foods were consumed. Also, intakes at the end of the run-in period were not different (data not shown). 
Body weight
During the study, mean body weight at the end of each period did not differ between interventions (P = 0.105) and was 93.3 6 12.6 kg when iGL test foods were consumed and 92.3 6 12.4 kg when dGL test foods were consumed. Body weights at the other time points (day 0 and day 21) were also not significantly different (data not shown).
Glucose and insulin metabolism
After 1 and 11 wk, fasting plasma glucose (Figure 1) , glycated hemoglobin, serum fructosamine, and fasting plasma insulin were comparable between the iGL and dGL interventions. The HOMA-IR also revealed no difference between both diets ( Table 4) .
Serum lipids and apolipoproteins
No statistically significant changes were observed between the iGL and dGL periods with regard to serum total cholesterol, LDL-cholesterol, HDL-cholesterol, and triacylglycerol concentrations and the total:HDL-cholesterol ratio after 11 wk of nutritional intervention. Apo A-I and apo B concentrations were also comparable between the 2 diet treatments ( Table 5 ). In addition, there were no short-term effects (after 1 or 5 wk) of the intervention on total, LDL-, and HDL-cholesterol concentrations and total:HDL cholesterol ( Figure 2 and Table 6 ).
Inflammation and prothrombotic markers
Mean hs-CRP concentration was not significantly different between the iGL and dGL periods. Concentrations of IL-6, TNFa, MCP-1, and active PAI-1 also did not change ( Table 7) .
DISCUSSION
In this intervention study with healthy overweight subjects at increased risk to develop metabolic syndrome, we observed that diets enriched with test foods with comparable macronutrient and fiber compositions, but with different GLs and GIs, did not change markers of metabolic syndrome. However, there was a difference in fructose intake. The difference in fructose intake between the iGL and dGL dietary periods (23.6 compared with 17.3 g) was 6.3 g, which corresponds with 1.25% of energy. From the literature, it is known that only a high fructose intake (20% of energy) can induce negative metabolic effects (19) . Thus, in this study, there would not be any effect of fructose on metabolic risk markers.
Earlier intervention studies on the effects of the GL or the GI on markers of glucose metabolism in nondiabetic overweight or obese subjects are inconsistent (20) . More recent intervention studies, however, suggested that fasting glucose concentrations are not influenced by a low-GI diet (21) (22) (23) (24) (25) . In contrast, results from a pilot study reported by Pal et al (26) indicated that consumption of a low-GI breakfast (GI of 35) for 3 wk lowered fasting glucose concentrations in 21 nondiabetic, normoglycemic, overweight subjects compared with the high-GI (GI of 79) breakfast. In contrast to other intervention studies (25, 27) , the macronutrient and fiber contents of the low-and the high-GI diets were comparable, which makes it possible to ascribe the beneficial effect to the GI only. As in our study, no improvements in fasting insulin concentrations and HOMA-IR were reported. Surprisingly, Sloth et al (23) observed in 45 overweight women that consumption for 10 wk of a diet with a decreased GI (GI of 72 compared with GI of 95) increased fasting glucose concentrations when compared with a diet with an increased GI (GI of 95). Macronutrient and dietary fiber intakes were comparable between the groups and could therefore not explain this effect. No treatment effects on fasting insulin concentrations were observed. Although these and our participants were at increased risk to develop metabolic syndrome, they had normal fasting glucose and insulin concentrations. Therefore, the potential beneficial effects of a low-GI or -GL diet are not consistent in nondiabetic populations, possibly because they are less susceptible to changes in glucose-insulin dynamics. This suggestion is further supported by the recent meta-analysis by Livesey et al (28), who observed clear evidence for beneficial effects of lower GI or GL diets on fasting plasma glucose concentrations only when concentrations were higher than 6 mmol/L. Thus, better glycemic control with low-GL or -GI products compared with high-GL or -GI products has been shown only in subjects who already have impaired glucose tolerance or who already have developed T2D. We further observed no evidence of an improvement in serum lipoprotein profile after consumption of dGL test foods for 11 wk.
This observation agrees with results from several recent studies in nondiabetic, overweight, or obese subjects (21, 22, 24, 26, 29) . In contrast, McMillan-Price et al (30) reported a decrease of 0.23 mmol/L in total cholesterol and of 0.21 mmol/L in LDLcholesterol concentrations in 27 subjects who consumed a low-GI diet (GI = 45) compared with 30 subjects who consumed a high-GI (GI of 70) diet. However, fiber intake in the low-GI group was 30 g/d compared with 23 g/d in the high-GI group, which was mainly due to increased consumption of legumes and products rich in whole grains. Although these products do not provide only soluble fibers, this may explain at least a part of the effect on serum lipoprotein profile. On the basis of a meta-analysis by Brown et al (31) , it can be estimated that a difference in soluble fiber intake of 7 g/d may cause a difference of '0.28 mmol/L in total cholesterol and of 0.21 mmol/L in LDL cholesterol. Furthermore, Sloth et al (23) observed a difference in LDL cholesterol of 0.22 mmol/L after 10 wk of a low-GI diet. In this study, macronutrient and fiber intakes between low-and high-GI groups were comparable. However, the low-GI test foods contained indigestible whole grains, whereas the high-GI test foods consisted of refined grains. Therefore, the GI was differently manipulated than in our study, which may explain the discrepancy in findings. Like many others (21, 22, 24, 30) , Sloth et al (23) also did not find a difference in HDL cholesterol after the intervention. This is in contrast with most epidemiologic data, which showed a positive effect of lowering the GL or GI on HDL cholesterol (32) (33) (34) . From these epidemiologic studies, it can be estimated that, by increasing the GL by 30 units, HDL cholesterol will decrease by 0.08 mmol/L. Thus, the sample size of our study was high enough to pick up such a difference. Finally, no effects on fasting serum triacylglycerol concentrations were observed, which agrees with most other intervention studies in nondiabetic subjects (20) .
Studies of GI effects on PAI-1 or other fibrinolytic parameters are very limited. We observed no difference in PAI-1 activity between iGL and dGL interventions. In contrast, Jensen et al (35) found a significant reduction (15%) in fasting PAI-1 concentrations when 44 healthy, overweight subjects consumed a decreased GI diet (GI of 72 compared with a GI of 95) for 10 wk. Thus, more intervention studies are needed to examine the effects of the GI and GL on the fibrinolytic system. Finally, metabolic syndrome is characterized by chronic lowgrade inflammation. Like others (36-38), we observed no changes in fasting hs-CRP concentrations. Moreover, our intervention had no effects on IL-6, TNF-a, and MCP-1 concentrations. To the best of our knowledge, there is only one other study that has examined the effects of different carbohydrates on inflammation markers in a longer-term trial (38) . Kallio et al (38) reported that whole-meal oat bread and potato (characterized by a high postprandial insulin response) increased concentrations of IL-1b and IL-6 after 12 wk compared with rye bread and pasta. This effect, however, was attributed to differences in postprandial insulin responses, because glucose responses were not different between the groups. In contrast, in a postprandial study with 16 overweight women (39) , no significant changes in plasma TNF-a, IL-1b, and IL-6 concentrations after a low-GI (GI of 37, GL of 42) or high-GI (GI of 77, GL of 86) meals were evident, despite difference in postprandial glucose and insulin concentrations. In addition, no changes in concentrations of monocytes expressing intracellular TNF-a and IL-1 b were reported. Finally, Dickinson et al (40) observed in a postprandial study a statistically significant increase of nuclear transcription factor B antigen in peripheral mononuclear cells after consumption of bread (high GI, 70) compared with pasta (low GI, 35) in 10 healthy volunteers. Taken together, effects of diets differing in GI and GL on inflammatory markers are not consistent.
To summarize, our results showed that consumption of test foods with a decreased GL did not ameliorate metabolic risk markers related to metabolic syndrome in healthy, overweight individuals. The lack of effect cannot be explained by the fact that adaptations in carbohydrate digestion or absorption may take place over time (41) , because after 1 or 5 wk of consumption of the experimental diets no effects were evident. However, a limitation of our study was that we could not calculate the GL or GI of the total diets, because food intake was estimated by using FFQs. Therefore, it cannot be excluded that, although the difference in GL between the experimental products was 32, the true difference in GL of the total diets was lower. Alternatively, it is possible that effects of the GL on the markers were less than anticipated, thereby lowering the statistical power of the design. Finally, even if our subjects were overweight or obese, their serum lipid and glucose concentrations were within normal ranges. As indicated previously, Livesey et al (28) reported beneficial effects of lower GL or GI diets only in subjects with increased fasting glucose concentrations. Thus, these issues need to be addressed in future studies to further clarify the role of food products with a decreased GL or GI on metabolic risk markers in subjects at increased risk of developing the metabolic syndrome.
We gratefully acknowledge the Bakery School and Cargill for delivering the test foods. We also thank the technical and dietary staff from the Department of Human Biology, Maastricht University, for their support. Finally, we thank our volunteers for their cooperation and enthusiasm.
The authors' responsibilities were as follows-RV: designed and conducted the study, performed the statistical analyses, interpreted the data, and wrote the manuscript; and RPM: designed the study, interpreted the data, had overall responsibility for the study, and wrote the manuscript. Neither of the authors had any financial or personal conflicts of interest.
